Montelukast-TEVA 10 mg, 28 tabs

$44.00

Montelukast-TEVA 10 mg, 28 tabs

As an additional treatment for bronchial asthma in patients with persistent mild to moderate asthma

Free International Shipping

 

Description

Montelukast-TEVA 10 mg, 28 tabs

Composition:
active substance: montelukast sodium;
1 coated tablet contains 10 mg montelukast (as montelukast sodium);
excipients: lactose monohydrate, hydroxypropyl cellulose; corn starch; sodium starch (type A); magnesium stearate sodium lauryl sulfate; shell Opadry 20A23676 Yellow: hydroxypropyl methylcellulose, hypromellose, titanium dioxide (E 171), iron dioxide yellow (E172), iron oxide red (E 172).

Pharmacotherapeutic group:
Means for systemic use in obstructive respiratory diseases. Leukotriene receptor antagonists. ATX code R03D C03.

Indications:

  • Additional treatment of persistent mild to moderate asthma, which is insufficiently controlled by inhaled corticosteroids, as well as in case of insufficient clinical control of asthma with short-acting β-agonists, used if necessary.
  • Relief of symptoms of seasonal and perennial allergic rhinitis.
  • Relieves symptoms of seasonal and allergic rhinitis in patients with bronchial asthma.
  • For the prevention of exercise-induced asthmatic attacks.

Contraindications:
Hypersensitivity to montelukast or to any component of the drug. Age up to 15 years (for a dose of 10 mg).

Method of administration and dosage:
The recommended dose for patients (aged 15 years and older) is 10 mg (1 tablet) per day, in the evening. To relieve the symptoms of allergic rhinitis, the time of admission is selected individually.

General recommendations
The therapeutic effect of the drug on asthma control indicators is observed within 1 day. Montelukast-Teva can be used with or without food. Patients are advised to continue taking Montelukast-Teva, even if the manifestations of their asthma are under control, just as during an exacerbation.
It is not recommended to use drug simultaneously with other drugs containing the same active substance – montelukast.

Special patient groups
There is no need for dose adjustment for elderly patients or patients with renal insufficiency, or mild or moderate liver dysfunction. There is no data on the use of the drug in patients with severe liver dysfunction.
The dosage is the same for men and women.

Montelukast-Teva and other medications for asthma. Therapy can be added to the patient’s existing asthma regimen.

Inhaled corticosteroids
Can be used as an adjunctive treatment for patients in whom inhaled corticosteroids, together with short-acting β-agonists, used as needed, do not provide satisfactory clinical control of the disease.
Should not be abruptly substituted for inhaled corticosteroids

Application features:
Patients should be warned that oral Montelukast-Teva should not be used to relieve acute asthma attacks, and that they should always carry the appropriate emergency medication with them. It is recommended to continue treatment with the usual appropriate medication for relieving seizures. In the event of an acute attack, short-acting inhaled β-agonists should be used. Patients need to consult a doctor as soon as possible if they need more than usual inhalations of short-acting β-agonists.
You should not abruptly replace therapy with montelukast for treatment with inhaled or oral corticosteroids. There is no evidence that oral corticosteroid intake can be reduced while montelukast is used.
In rare cases, patients receiving anti-asthma drugs, including montelukast, may experience systemic eosinophilia, sometimes together with clinical manifestations of vasculitis, the so-called Churg-Strauss syndrome (granulomatous allergic angiitis), which is treated with systemic corticosteroids. Such cases are usually (but not always) associated with a decrease or cancellation of GCS therapy.
The likelihood that leukotriene receptor antagonists may be associated with the emergence of Churg-Strauss syndrome cannot be refuted or confirmed, therefore doctors should be careful about the occurrence of eosinophilia in patients, Vasculitis rashes, worsening pulmonary symptoms, heart complications and / or neuropathy … Patients who develop the aforementioned symptoms should be re-evaluated and their treatment regimen should be re-evaluated.
Shelf life:
3 years.
Storage conditions:
Does not require special storage conditions. Store the blister in a cardboard box to protect it from light.
Packaging:  There are 7 tablets in a blister, 4 blisters in a cardboard box.
 
Produced in Poland